<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02652312</url>
  </required_header>
  <id_info>
    <org_study_id>Anesthesia 110T</org_study_id>
    <nct_id>NCT02652312</nct_id>
  </id_info>
  <brief_title>Dexmedetomidine and Desflurane Consumption</brief_title>
  <official_title>Effect of Dexmedetomidine Infusion on Desflurane Consumption and Hemodynamics During BIS Guided Laparoscopic Surgery: A Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Theodor Bilharz Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Theodor Bilharz Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to calculate desflurane consumption when combined with
      intraoperative dexmedetomidine infusion guided by bispectral index (BIS)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Forty patients will be randomly allocated into two equal groups as Group 'D' (Dexmedetomidine
      group) and Group 'P' (Placebo group) using computer generated random numbers. After arrival
      in the operating room, ondansetron 0.15 mg/kg intravenous (IV) will be given as a
      pre-medication. Ringer's acetate solution (500 ml) will be infused as a preload then at a
      rate of 6-8 ml/kg/h during surgery for supplying maintenance and deficit. Monitoring
      consisted of continuous electrocardiogram (EKG), non-invasive blood pressure (NIBP), pulse
      oximetry (SpO2), CO2 expired fraction (ETCO2), desflurane inspired fraction (FIdes), and
      desflurane expired fraction (ETdes) (Infinity Kappa, Dräger, Lübeck, Germany) will be
      attached to the patient. BIS module (InfinityR BISxTM SmartPodR, smoothing rate: 15 or 30
      seconds, software revision: VF5) will also be attached for detection of consciousness level.

      All patients will be preoxygenated with 100% oxygen for 3 minutes. The patients in group D
      will receive dexmedetomidine (2 ml diluted in 18 ml of saline) IV in a dose of 1 mcg/kg
      over10 minutes through infusion pump prior to induction. Group P patients will receive
      similar volume of normal saline over 10 min. The study drug and placebo infusions will be
      prepared by an anesthesiologist who is not involved in the study and the anesthesiologist
      recording the details is unaware of the type of infusion patients received. Anesthesia will
      be induced with IV fentanyl 1.5 μg/kg and propofol in a dose of 10 mg every 5 seconds until
      the BIS level dropped below 60 and confirmed with loss of response to verbal commands. In
      both groups, Atracurium 0.5 mg/kg IV will be administered, and trachea will be intubated.
      Fresh gas flow oxygen in air 30-40% at a rate of 3 L/min for 10 minutes will be administered
      then the flow will be decreased at a rate of 1 L/min using a closed system (Fabius GS,
      Dräger, Lübeck, Germany) and ventilation will be adjusted to maintain end-tidal carbon
      dioxide at 30-35 mmHg. Patients in study groups will receive the volatile agent at a
      concentration of 1 MAC (Minimum Alveolar Concentration). The MAC of desflurane is defined as
      an expired fraction of 6.0 vol%. Then the dial-up desflurane percentage will be adjusted to
      establish a BIS value between 40- 50. A maintenance dose of Dexmedetomidine infusion at 0.5
      mcg/kg/hour made to 20 mL with normal saline will be administered in group D patients and a
      similar volume of normal saline will be administered in Group P, till the end of surgery. Top
      up doses of Atracurium will be given as needed. When heart rate and blood pressure exceeds
      20% of baseline in spite of adequate level of anesthesia guided by BIS, boluses of 0.5 μg/kg
      will be given. While decrease in heart rate and blood pressure more than 20% of baseline,
      will be treated by ephedrine 5 mg.

      In both groups, dexmedetomidine or saline will be stopped approximately 15-20 minutes before
      completion of surgery, diclofenac sodium 1 mg/kg will be given IM at the time of skin
      closure. Desflurane will be discontinued after skin closure in both groups. Reversal of
      neuromuscular blockade will be achieved with neostigmine 0.05 mg/kg and atropine 0.02 mg/kg.
      Tracheal extubation will be done when respiration is satisfactory and adequate muscle tone is
      achieved
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>desflurane consumption (ml)</measure>
    <time_frame>Intraoperative</time_frame>
    <description>Calculation of desflurane consumption during the intraoperative period</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Heart Rate (Beat/min)</measure>
    <time_frame>Intraoperative</time_frame>
    <description>Recording of the heart rate during the intraoperative period before induction, after induction, after intubation, and then at 5, 10, 15, 30, 45, and 60 minute after intubation and at extubation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Pressure (mm Hg)</measure>
    <time_frame>Intraoperative</time_frame>
    <description>Recording of the heart rate during the intraoperative period before induction, after induction, after intubation, and then at 5, 10, 15, 30, 45, and 60 minute after intubation and at extubation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fentanyl consumption (ug)</measure>
    <time_frame>Intraoperative</time_frame>
    <description>Total intraoperative fentanyl consumption</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Anesthesia</condition>
  <arm_group>
    <arm_group_label>Group 'D'</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dexmedetomidine group Patients received dexmedetomidine (2 ml diluted in 18 ml of saline) IV in a dose of 1 mcg/kg over 10 minutes. A maintenance dose of Dexmedetomidine infusion at 0.5 mcg/kg/hour was infused.
Ondansetron: 0.15 mg/kg intravenous preoperative. Fentanyl: 1.5 μg/kg intraoperative Propofol: 10 mg every 5 seconds until the BIS level dropped below 60 for induction of anesthesia.
Atracurium: 0.5 mg/kg IV. Desflurane: 1 MAC concentration. Diclofenac sodium: 1 mg/kg for postoperative analgesia.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 'P'</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo group Patients received similar volume of normal saline as the bolus and maintenance infusion as group D.
Ondansetron: 0.15 mg/kg intravenous preoperative. Fentanyl: 1.5 μg/kg intraoperative Propofol: 10 mg every 5 seconds until the BIS level dropped below 60 for induction of anesthesia.
Atracurium: 0.5 mg/kg IV. Desflurane: 1 MAC concentration. Diclofenac sodium: 1 mg/kg for postoperative analgesia.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>A maintenance dose of Dexmedetomidine infusion at 0.5 mcg/kg/hour made to 20 mL with normal saline will be administered</description>
    <arm_group_label>Group 'D'</arm_group_label>
    <other_name>Precedex</other_name>
    <other_name>Dexdor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>A maintenance dose of 20 mL with normal saline will be administered at a rate similar to that of dexmedetomidine</description>
    <arm_group_label>Group 'P'</arm_group_label>
    <other_name>placebo effect</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ondansetron</intervention_name>
    <description>0.15 mg/kg intravenous (IV) will be given as a pre-medication</description>
    <arm_group_label>Group 'D'</arm_group_label>
    <arm_group_label>Group 'P'</arm_group_label>
    <other_name>Zofran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>fentanyl</intervention_name>
    <description>1.5 μg/kg intraoperative</description>
    <arm_group_label>Group 'D'</arm_group_label>
    <arm_group_label>Group 'P'</arm_group_label>
    <other_name>Sublimaze,Actiq, Durogesic, Duragesic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>propofol</intervention_name>
    <description>10 mg every 5 seconds until the BIS level dropped below 60 for induction of anesthesia</description>
    <arm_group_label>Group 'D'</arm_group_label>
    <arm_group_label>Group 'P'</arm_group_label>
    <other_name>Diprivan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Atracurium</intervention_name>
    <description>0.5 mg/kg IV for endotracheal intubation</description>
    <arm_group_label>Group 'D'</arm_group_label>
    <arm_group_label>Group 'P'</arm_group_label>
    <other_name>Atracurium besilate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>diclofenac sodium</intervention_name>
    <description>1 mg/kg for postoperative analgesia</description>
    <arm_group_label>Group 'D'</arm_group_label>
    <arm_group_label>Group 'P'</arm_group_label>
    <other_name>Voltaren</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>desflurane</intervention_name>
    <description>1 MAC concentration (expired fraction of 6.0 vol%) for maintenance of anesthesia</description>
    <arm_group_label>Group 'D'</arm_group_label>
    <arm_group_label>Group 'P'</arm_group_label>
    <other_name>Suprane</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  American Society of Anesthesiologists (ASA) status of I and II

          -  undergoing elective laparoscopic cholecystectomy

        Exclusion Criteria:

          -  history of psychiatric/neurological illness

          -  cardiovascular disease

          -  morbid obese patients

          -  pregnant and nursing women

          -  known allergic reaction to any of the study medication

          -  recent use of sedatives or analgesics
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Abla El Hadidy, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Theodor Bilharz Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Theodor Bilharz Research Institute</name>
      <address>
        <city>Giza</city>
        <zip>12411</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Harsoor SS, Rani DD, Lathashree S, Nethra SS, Sudheesh K. Effect of intraoperative Dexmedetomidine infusion on Sevoflurane requirement and blood glucose levels during entropy-guided general anesthesia. J Anaesthesiol Clin Pharmacol. 2014 Jan;30(1):25-30. doi: 10.4103/0970-9185.125693.</citation>
    <PMID>24574589</PMID>
  </reference>
  <reference>
    <citation>Kamibayashi T, Maze M. Clinical uses of alpha2 -adrenergic agonists. Anesthesiology. 2000 Nov;93(5):1345-9. Review.</citation>
    <PMID>11046225</PMID>
  </reference>
  <reference>
    <citation>Nishibe S, Imanishi H, Mieda T, Tsujita M. The effects of dexmedetomidine administration on the pulmonary artery pressure and the transpulmonary pressure gradient after the bidirectional superior cavopulmonary shunt. Pediatr Cardiol. 2015 Jan;36(1):151-7. doi: 10.1007/s00246-014-0979-2. Epub 2014 Aug 12.</citation>
    <PMID>25113519</PMID>
  </reference>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 6, 2016</study_first_submitted>
  <study_first_submitted_qc>January 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2016</study_first_posted>
  <last_update_submitted>November 9, 2016</last_update_submitted>
  <last_update_submitted_qc>November 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 10, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Theodor Bilharz Research Institute</investigator_affiliation>
    <investigator_full_name>Yasser Mostafa Samhan</investigator_full_name>
    <investigator_title>Professor of Anesthesia</investigator_title>
  </responsible_party>
  <keyword>Dexmedetomidine</keyword>
  <keyword>Desflurane</keyword>
  <keyword>Bispectral Index BIS</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Fentanyl</mesh_term>
    <mesh_term>Desflurane</mesh_term>
    <mesh_term>Isoflurane</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Ondansetron</mesh_term>
    <mesh_term>Diclofenac</mesh_term>
    <mesh_term>Atracurium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

